A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry.
8q24
African ancestry
Familial prostate cancer
Family history
Genetic variant
Genetics
Health disparities
Prostate cancer
Journal
European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
24
01
2020
accepted:
23
04
2020
pubmed:
16
5
2020
medline:
16
7
2021
entrez:
16
5
2020
Statut:
ppublish
Résumé
Although men of African ancestry have a high risk of prostate cancer (PCa), no genes or mutations have been identified that contribute to familial clustering of PCa in this population. We investigated whether the African ancestry-specific PCa risk variant at 8q24, rs72725854, is enriched in men with a PCa family history in 9052 cases, 143 cases from high-risk families, and 8595 controls of African ancestry. We found the risk allele to be significantly associated with earlier age at diagnosis, more aggressive disease, and enriched in men with a PCa family history (32% of high-risk familial cases carried the variant vs 23% of cases without a family history and 12% of controls). For cases with two or more first-degree relatives with PCa who had at least one family member diagnosed at age <60 yr, the odds ratios for TA heterozygotes and TT homozygotes were 3.92 (95% confidence interval [CI] = 2.13-7.22) and 33.41 (95% CI = 10.86-102.84), respectively. Among men with a PCa family history, the absolute risk by age 60 yr reached 21% (95% CI = 17-25%) for TA heterozygotes and 38% (95% CI = 13-65%) for TT homozygotes. We estimate that in men of African ancestry, rs72725854 accounts for 32% of the total familial risk explained by all known PCa risk variants. PATIENT SUMMARY: We found that rs72725854, an African ancestry-specific risk variant, is more common in men with a family history of prostate cancer and in those diagnosed with prostate cancer at younger ages. Men of African ancestry may benefit from the knowledge of their carrier status for this genetic risk variant to guide decisions about prostate cancer screening.
Identifiants
pubmed: 32409115
pii: S0302-2838(20)30328-6
doi: 10.1016/j.eururo.2020.04.060
pmc: PMC7805560
mid: NIHMS1610142
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
316-320Subventions
Organisme : NCI NIH HHS
ID : U10 CA037429
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA165862
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189974
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA214253
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA148537
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014236
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA196569
Pays : United States
Organisme : NCI NIH HHS
ID : K99 CA246063
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES010126
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Références
N Engl J Med. 2012 Jan 12;366(2):141-9
pubmed: 22236224
Nat Genet. 2007 May;39(5):638-44
pubmed: 17401364
Neoplasia. 2014 Nov 20;16(11):900-8
pubmed: 25425964
J Clin Oncol. 2018 Feb 1;36(4):414-424
pubmed: 29236593
Nat Commun. 2018 Nov 5;9(1):4616
pubmed: 30397198
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 29117387
Prostate. 2019 Mar;79(4):333-339
pubmed: 30450585
Epidemiol Rev. 2001;23(1):19-23
pubmed: 11588848
Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4173-8
pubmed: 24594601
Hum Genet. 2013 Jan;132(1):5-14
pubmed: 23064873
Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14068-73
pubmed: 16945910